Danette Daniels Email

VP, Protein Degradation Platform . Foghorn Therapeutics

Current Roles

Employees:
162
Revenue:
$22.9M
About
More than 20,000 genes make us human. Genes control critical aspects of health and disease but what controls our genes A Flagship Pioneering company, Foghorn Therapeutics is developing therapies based on a system that directs which genes our cells express, and when, where, and in what order. By manipulating this system with our unique Gene Traffic Control(TM) platform, Foghorn will change how genes turn on and off. Unlike approaches that edit genes, this novel way of thinking will alter what our DNA has in store for usand rewrite destiny for millions of people living with disease. With Gene Traffic Control(TM) Foghorn is pioneering a new, major class of drug targets to develop unprecedented therapies for cancer and other serious diseases. We have already validated multiple targets, are in the process of developing drug candidates in multiple types of cancer and are beginning to explore other diseases.
Foghorn Therapeutics Address
500 Technology Square
Cambridge, MA
United States
Foghorn Therapeutics Email

Past Companies

Foghorn Therapeutics, IncVice President, Protein Degradation Platform
PromegaGroup Leader, Functional Proteomics

#1 Startup Dataset

Growth rates, revenue data, direct competitors and contact details.